Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Yıl: 2021 Cilt: 51 Sayı: 4 Sayfa Aralığı: 1615 - 1623 Metin Dili: İngilizce DOI: 10.3906/sag-2012-5 İndeks Tarihi: 10-01-2022

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Öz:
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.Key words: COVID-19, biologic DMARDs, rheumatoid arthritis, spondyloarthritis
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
4
7
7
  • 1. Carrillo-Vega MF, Salinas-Escudero G, Garcia-Pena C, Gutierrez-Robledo LM, Parra-Rodriguez L. Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. Plos One 2020; 15 (9): e0238905. Doi: 10.1371/ journal.pone.0238905
  • 2. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases 2020; 79 (7): 859- 866. Doi: 10.1136/annrheumdis-2020-217871
  • 3. Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. Journal of Community Health 2020; 45 (6): 1270-1282. doi: 10.1007/ s10900-020-00920-x
  • 4. Landewe RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-cov-2. Annals of the Rheumatic Diseases 2020; 79 (7): 851-858. doi: 10.1136/annrheumdis-2020-217877
  • 5. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis and Rheumatology 2020; 72 (9): e1-e12. doi: 10.1002/art.41437
  • 6. Babaoglu H. Türkiye Romatoloji Derneği Romatoloji uzmanlari için koronavirüs (Covid-19) salgını sırasında hastalık yönetimi önerileri. Journal of Turkish Society of Rheumatology 2020; 12 (1):1-2 (in Turkish). doi: 10.4274/raed.galenos.2020.99609
  • 7. Kalyoncu U, Tascilar EK, Ertenli AI, Dalkilic HE, Bes C et al. Methodology of a new inflammatory arthritis registry: treasure. Turkish Journal of Medical Sciences 2018; 48 (4): 856- 861. doi: 10.3906/sag-1807-200
  • 8. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatology 1984; 27 (4): 361-368. doi: 10.1002/ art.1780270401
  • 9. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N et al. The development of Assessment of spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the Rheumatic Diseases 2009; 68 (6): 777-783. doi:
  • 10.1136/ard.2009.108233 10. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J et al. The Assessment of spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases 2011; 70 (1): 25-31. doi: 10.1136/ard.2010.133645
  • 11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatology 2006; 54 (8): 2665-2673. doi: 10.1002/art.21972
  • 12. Esatoglu SN, Tascilar K, Babaoglu H, Bes C, Yurttas B et al. COVID-19 among patients with inflammatory rheumatic diseases, PREPRINT (Version 1) available at Research Square. Dec 2020. doi: 10.21203/rs.3.rs-115378/v1
  • 13. Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis and Rheumatology 2020; 72 (10): 1600-1606. doi: 10.1002/art.41388
APA Kalyoncu U, PEHLİVAN Y, Akar S, KASIFOGLU T, Kimyon G, Karadag O, Dalkılıç E, Ertenli I, Kılıç L, Ersozlu E, Bes C, emmungil h, mercan r, Durak Ediboglu E, Alpay Kanıtez N, Bilgin E, YURUMEZ COLAK S, Koca S, Gönüllü E, kucuksahin o, Coskun B, KİRAZ S, Yağız B (2021). Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. , 1615 - 1623. 10.3906/sag-2012-5
Chicago Kalyoncu Umut,PEHLİVAN Yavuz,Akar Servet,KASIFOGLU TIMUCIN,Kimyon Gezmiş,Karadag Omer,Dalkılıç Ediz,Ertenli Ihsan,Kılıç Levent,Ersozlu Emine Duygu,Bes Cemal,emmungil hakan,mercan ridvan,Durak Ediboglu Elif,Alpay Kanıtez Nilüfer,Bilgin Emre,YURUMEZ COLAK SEDA,Koca Suleyman Serdar,Gönüllü Emel,kucuksahin orhan,Coskun Belkis Nihan,KİRAZ SEDAT,Yağız Burcu Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. (2021): 1615 - 1623. 10.3906/sag-2012-5
MLA Kalyoncu Umut,PEHLİVAN Yavuz,Akar Servet,KASIFOGLU TIMUCIN,Kimyon Gezmiş,Karadag Omer,Dalkılıç Ediz,Ertenli Ihsan,Kılıç Levent,Ersozlu Emine Duygu,Bes Cemal,emmungil hakan,mercan ridvan,Durak Ediboglu Elif,Alpay Kanıtez Nilüfer,Bilgin Emre,YURUMEZ COLAK SEDA,Koca Suleyman Serdar,Gönüllü Emel,kucuksahin orhan,Coskun Belkis Nihan,KİRAZ SEDAT,Yağız Burcu Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. , 2021, ss.1615 - 1623. 10.3906/sag-2012-5
AMA Kalyoncu U,PEHLİVAN Y,Akar S,KASIFOGLU T,Kimyon G,Karadag O,Dalkılıç E,Ertenli I,Kılıç L,Ersozlu E,Bes C,emmungil h,mercan r,Durak Ediboglu E,Alpay Kanıtez N,Bilgin E,YURUMEZ COLAK S,Koca S,Gönüllü E,kucuksahin o,Coskun B,KİRAZ S,Yağız B Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. . 2021; 1615 - 1623. 10.3906/sag-2012-5
Vancouver Kalyoncu U,PEHLİVAN Y,Akar S,KASIFOGLU T,Kimyon G,Karadag O,Dalkılıç E,Ertenli I,Kılıç L,Ersozlu E,Bes C,emmungil h,mercan r,Durak Ediboglu E,Alpay Kanıtez N,Bilgin E,YURUMEZ COLAK S,Koca S,Gönüllü E,kucuksahin o,Coskun B,KİRAZ S,Yağız B Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. . 2021; 1615 - 1623. 10.3906/sag-2012-5
IEEE Kalyoncu U,PEHLİVAN Y,Akar S,KASIFOGLU T,Kimyon G,Karadag O,Dalkılıç E,Ertenli I,Kılıç L,Ersozlu E,Bes C,emmungil h,mercan r,Durak Ediboglu E,Alpay Kanıtez N,Bilgin E,YURUMEZ COLAK S,Koca S,Gönüllü E,kucuksahin o,Coskun B,KİRAZ S,Yağız B "Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic." , ss.1615 - 1623, 2021. 10.3906/sag-2012-5
ISNAD Kalyoncu, Umut vd. "Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic". (2021), 1615-1623. https://doi.org/10.3906/sag-2012-5
APA Kalyoncu U, PEHLİVAN Y, Akar S, KASIFOGLU T, Kimyon G, Karadag O, Dalkılıç E, Ertenli I, Kılıç L, Ersozlu E, Bes C, emmungil h, mercan r, Durak Ediboglu E, Alpay Kanıtez N, Bilgin E, YURUMEZ COLAK S, Koca S, Gönüllü E, kucuksahin o, Coskun B, KİRAZ S, Yağız B (2021). Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, 51(4), 1615 - 1623. 10.3906/sag-2012-5
Chicago Kalyoncu Umut,PEHLİVAN Yavuz,Akar Servet,KASIFOGLU TIMUCIN,Kimyon Gezmiş,Karadag Omer,Dalkılıç Ediz,Ertenli Ihsan,Kılıç Levent,Ersozlu Emine Duygu,Bes Cemal,emmungil hakan,mercan ridvan,Durak Ediboglu Elif,Alpay Kanıtez Nilüfer,Bilgin Emre,YURUMEZ COLAK SEDA,Koca Suleyman Serdar,Gönüllü Emel,kucuksahin orhan,Coskun Belkis Nihan,KİRAZ SEDAT,Yağız Burcu Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences 51, no.4 (2021): 1615 - 1623. 10.3906/sag-2012-5
MLA Kalyoncu Umut,PEHLİVAN Yavuz,Akar Servet,KASIFOGLU TIMUCIN,Kimyon Gezmiş,Karadag Omer,Dalkılıç Ediz,Ertenli Ihsan,Kılıç Levent,Ersozlu Emine Duygu,Bes Cemal,emmungil hakan,mercan ridvan,Durak Ediboglu Elif,Alpay Kanıtez Nilüfer,Bilgin Emre,YURUMEZ COLAK SEDA,Koca Suleyman Serdar,Gönüllü Emel,kucuksahin orhan,Coskun Belkis Nihan,KİRAZ SEDAT,Yağız Burcu Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, vol.51, no.4, 2021, ss.1615 - 1623. 10.3906/sag-2012-5
AMA Kalyoncu U,PEHLİVAN Y,Akar S,KASIFOGLU T,Kimyon G,Karadag O,Dalkılıç E,Ertenli I,Kılıç L,Ersozlu E,Bes C,emmungil h,mercan r,Durak Ediboglu E,Alpay Kanıtez N,Bilgin E,YURUMEZ COLAK S,Koca S,Gönüllü E,kucuksahin o,Coskun B,KİRAZ S,Yağız B Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences. 2021; 51(4): 1615 - 1623. 10.3906/sag-2012-5
Vancouver Kalyoncu U,PEHLİVAN Y,Akar S,KASIFOGLU T,Kimyon G,Karadag O,Dalkılıç E,Ertenli I,Kılıç L,Ersozlu E,Bes C,emmungil h,mercan r,Durak Ediboglu E,Alpay Kanıtez N,Bilgin E,YURUMEZ COLAK S,Koca S,Gönüllü E,kucuksahin o,Coskun B,KİRAZ S,Yağız B Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences. 2021; 51(4): 1615 - 1623. 10.3906/sag-2012-5
IEEE Kalyoncu U,PEHLİVAN Y,Akar S,KASIFOGLU T,Kimyon G,Karadag O,Dalkılıç E,Ertenli I,Kılıç L,Ersozlu E,Bes C,emmungil h,mercan r,Durak Ediboglu E,Alpay Kanıtez N,Bilgin E,YURUMEZ COLAK S,Koca S,Gönüllü E,kucuksahin o,Coskun B,KİRAZ S,Yağız B "Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic." Turkish Journal of Medical Sciences, 51, ss.1615 - 1623, 2021. 10.3906/sag-2012-5
ISNAD Kalyoncu, Umut vd. "Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic". Turkish Journal of Medical Sciences 51/4 (2021), 1615-1623. https://doi.org/10.3906/sag-2012-5